AbbVieABBV

• Phase ?축성 척추관절염 환자 대상 우파다시티닙 실사용 임상모집 중A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
  59%
• Phase 3소아 중증 궤양성 대장염 환자 대상 경구용 우파다시티닙 임상진행 중Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
  89%
• Phase ?중등도-중증 건선 대상 리산키주맙 삶의 질 개선 평가모집 중Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
  59%
• Phase ?우파다시티닙 중등도-중증 아토피 실제 처방 연구모집 중An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
  80%
• Phase 3청소년 궤양성 대장염 환자 대상 리산키주맙 임상모집 중A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
  79%
• Phase 3베네토클락스 이전 임상 참여자 대상 연장 임상진행 중An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
  66%
• Phase 3리산키주맙 소아 크론병 치료 임상모집 중A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
  79%
• Phase 3소아청소년 편두통 환자 대상 아토게판트 임상모집 중A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
  51%
• Phase 3유브로게판트 성인 월경성 편두통 치료 임상모집 중Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
  47%
• Phase 3유브로게판트 소아·청소년 급성 편두통 임상모집 중Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  47%
• Phase 3우파다시티닙 소아 중등도-중증 크론병 치료 임상모집 중Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
  20%
• Phase ?궤양성 대장염 대상 우파다시티닙 경구제 유효성 임상모집 중Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
  80%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.